 Home > Medical News > Medicines Company News > Innovent will present a number of clinical data at the 2022 ESMO IO Conference and ASH Annual Meeting

Innovent will present a number of clinical data at the 2022 ESMO IO Conference and ASH Annual Meeting

 Last Update: 2023-01-01
 Source: Internet
 Author: User

Tags

different cancer treatments

all phase mechanical

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Innovent Biopharmaceutical Group (HKEx stock code: 01801), a biopharmaceutical company dedicated to the development, production and sale of innovative drugs in the field of major diseases such as oncology, autoimmunity, metabolism, ophthalmology, etc.
, announced that it has cooperated with Daboshu ^® (Cindilimab injection), Nerick ^® (orebatinib), IBI188 (anti-CD47 monoclonal antibody), Five latest clinical data related to IBI110 (anti-LAG-3 monoclonal antibody) and IBI939 (anti-TIGIT monoclonal antibody) will be announced
at the upcoming international academic conference.
A brief summary is as follows:

European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress

Conference time: December 7-9, 2022

(1) Report: Efficacy and safety of IBI110 (anti-LAG-3 monoclonal antibody) combined with sindilimab in advanced squamous non-small cell lung cancer: updated results of the Phase Ib study

Report type: Poster report

Poster number: 86P

Principal Investigator: Prof.
Caicun Zhou (Shanghai Pulmonary Hospital)

Prof.
Nong Xu (The First Affiliated Hospital of Zhejiang University School of Medicine)

(ii) Report: Efficacy and safety of IBI939 (anti-TIGIT monoclonal antibody) combined with sindilimab in first-line advanced PD-L1 high-expression non-small cell lung cancer: results of the Phase Ib study

Report type: Poster report

Poster number: 77P

Principal Investigator: Prof.
Ying Cheng (Jilin Cancer Hospital)

64th Annual Meeting of the American Society of Hematology (ASH).

Conference time: December 10-13, 2022

(1) Report: Efficacy and safety of IBI188 (CD47) combined with azacitidine in first-line diagnosis of high-risk myelodysplastic syndromes: phase Ib study results

Report type: Poster report

Poster number: 1759

Principal investigator: Prof.
Xiao Zhijian (Hematology Hospital, Chinese Academy of Medical Sciences) - corresponding author

Prof.
Miao Zhi (The First Affiliated Hospital of Soochow University) - first author

(ii) Report: The latest results of the pivotal phase II clinical trial of orebatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant T315I mutant chronic myeloid leukemia chronic and accelerated phase (CML-CP and CML-AP).

Report Type: Oral presentation

Abstract number: 170698

Principal Investigator: Prof.
Qian Jiang (Peking University People's Hospital)

(3) Report: 5-year safety and efficacy follow-up data of a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI) orebatinib (HQP1351) in Chinese TKI-resistant chronic myeloid leukemia (CML) patients

Report Type: Oral presentation

Abstract number: 170868

Principal Investigator: Prof.
Qian Jiang (Peking University People's Hospital)

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.